Tag: stage

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.

New York, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that Matthew Barry has joined the Company as its Director of Investor Relations.

BOCA RATON, FL, June 16, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced its support for the launch of a new dfdvSOL / SOL liquidity pool on Orca, one of the leading Solana-native decentralized exchanges. The pool, deployed on Orca’s flagship Concentrated Liquidity Market Maker (CLMM), introduces new utility and yield opportunities for dfdvSOL holders, while contributing to long-term growth in SOL per share (SPS).

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

ZURICH, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Next month, Switzerland is hosting UEFA Women's EURO 2025. For the first time, the president of a host nation has addressed the fans of a major event directly, declaring their support for the sport and all the teams competing. This morning, the Swiss president Karin Keller-Sutter released an official video which sends a clear message: Switzerland attaches great importance to UEFA Women's EURO 2025 and the role the host nation has to play.